Evotec AG (FSE: EVT, TecDAX)

https://www.evotec.com

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *

	Start	2005-06-24 renamed
	End	2019-04-01 restructured
	Group	Evotec (Group)
	Today	Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
	Predecessor	Evotec OAI AG
	Successor	Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
	Industry	drug discovery technology
	Industry 2	drug discovery services
	Person	Lanthaler, Werner (Evotec AG 200903–202401 CEO before Intercell + Austrian Industrial Assoc + McKinsey RESIGNED 1/24)
	Person 2	Spillner, Enno (Formycon 202304– CFO before Evotec + 4SC + BioM Venture Capital GmbH)

	Region	Hamburg
	Country	Germany
	Street	7 Essener Bogen Manfred Eigen Campus
	City	22419 Hamburg
	Tel	+49-40-56081-0
		Address record changed: 2024-01-05

Basic data	Employees	F: 1,001 to 5,000 (2018-12-31)
	Currency	EUR
	Annual sales	375,405,000 (revenues, consolidated (2018) 2018-12-31)
	Profit	84,056,000 (2018-12-31)
	Cash	109,055,000 (2018-12-31)

		* Document for »About Section«:

		Record changed: 2023-12-30